WINNER OF SOPA!
David’s Fortune article on India was part of a special issue that won an award for excellence from the Society of Publishers in Asia (SOPA), the Pulitzers of Asia. Check out the article
on David’s media page. Click here for the press release from SOPA.
NEW BOOK OUT ON MAY 10, 2005 IN THE U.S.
The Geneticist Who Played Hoops with My DNA:
and other masterminds from the frontiers of biotech
Published by Harper-Collins in the US, and in the UK in August, 2005 by Fourth Estate/HarperCollins. Check out a sample of the book... Order an advance copy now from
Amazon.
David recently returned from shooting on location in Micronesia as a correspondent and writer for the new PBS NOVA science magazine program,
ScienceNow!. Look for his segment on the Science of Obesity airing in July, 2005. ALSO, David has just finished a segment on brain implants for NPR's
Morning Edition that is a "reported commentary", a new style of commentary that combines a reported piece with opinion. Look for this to air in mid-March on Morning Edition.
COLUMN, “BIOTECH AND CREATIVITY”, TWICE MONTHLY
After one year, the column has covered everything from stem cells and increasing lifespan to the return of Dr. Faustus and the role of science in politics… Look for it every-other-Sunday in the San Francisco Chronicle, or
online, or on this site in the
media section. National syndication is on the way…
AAAS JOURNALISM AWARD – BEST MAGAZINE STORY, 2004
David received the prestigious
AAAS Science Journalism Award for best magazine story, 2004, given by the American Association for the Advancement of Science, for the article “DNA as Destiny”, in Wired.
BIOAGENDA GOES NON-PROFIT
BioAgenda -- co-founded by David -- enters its second year after a successful first year having recently been provisionally approved by the IRS as a nonprofit, 501 c(3) corporation. BioAgenda is designed as an independent, journalistic program that gathers scientists, journalists, policy makers, business leaders, advocates, critics, and artists representing all points of view on issues ranging from stem cells to drug pricing. David is the unpaid founder and editorial director in charge of content and educational activities.
